Cuba - spansk - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

zhejiang ruixin pharmaceutical co. ltd.. - sulfato de atropina - inyección iv, im - 0,5 mg/ml

Cuba - spansk - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

zhejiang ruixin pharmaceutical co. ltd.. - agua estéril para inyección - diluente para inyección im e iv - 5 ml

Cuba - spansk - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

zhejiang tianrui pharmaceutical co., ltd. - cloruro de potasio - solución para inyección iv. - 1,5 g/10 ml

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied.

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - paroxetine hydrochloride anhydrous (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - major depressive disorder: paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied.

Kamerun - fransk - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

zhejiang yatai pharmaceutical co ltd - albendazole - comprimé / tablet - 200 mg

Kamerun - fransk - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

zhejiang yatai pharmaceutical co ltd - azithromycine - comprimé / tablet - 250 mg

Kamerun - fransk - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

zhejiang yatai pharmaceutical co ltd - ciprofloxacine - comprimé / tablet - 250 mg

Panama - engelsk - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

zhejiang chimin pharmaceutical co., ltd - metronidazol - metronidazol....500mg

Panama - engelsk - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

zhejiang chimin pharmaceutical co., ltd - glucosa - glucosa....5 g / cloruro de sodio....0.9 g